our Premium Content: News alerts, weekly reports and conference planners

GENE:

MMP11 (Matrix Metallopeptidase 11)

News alerts, weekly reports and conference planners

Development of a HER1/CP2c dual-targeting biopharmaceutical for HER1-overexpressing head and neck cancer. (PubMed, Biomater Adv)

Moreover, it showed no adverse reactions in immune cells and normal cells. In conclusion, DTAT-D351, herein called Cetuximab scFv-CPTin, is a promising and effective anticancer agent for the treatment of HER1-overexpressing cancer cells, including head and neck cancers.

2 days ago

Journal

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • MMP11 (Matrix Metallopeptidase 11)

Erbitux (cetuximab)

Spatially Resolved Transcriptomics Identifies Tumor-Stroma-Immune Networks and Therapeutic Targets in Endocrine-Resistant Advanced Breast Cancer Treated with Everolimus+Letrozole: Insights from the MIRACLE Trial. (PubMed, Cancer Lett)

This finding suggests that tasquinimod, an S100A9 inhibitor, could be a viable therapeutic option. Furthermore, the interaction between MMP11 and COL16A1 in stroma-rich regions suggests that cancer-associated fibroblasts may contribute to improved outcomes. Our study underscores the critical role of spatial gene expression analysis in elucidating the tumor microenvironment and its impact on prognosis in patients undergoing E+L treatment, thereby opening new avenues for targeted interventions.

3 days ago

Journal

HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • S100A9 (S100 Calcium Binding Protein A9) • MMP11 (Matrix Metallopeptidase 11) • FKBP5 (FKBP Prolyl Isomerase 5) • SERPINA1 (Serpin Family A Member 1)

HR positive • HER-2 amplification + HR-positive

everolimus • letrozole • tasquinimod (ABR-215050)

13d

Expression and Clinical Significance of FOXQ1, MMP11, and CST1 in Colorectal Cancer. (PubMed, Clin Lab)

The research data indicate that the abnormal overexpression of FOXQ1, MMP11, and CST1 in CRC tissues is significantly correlated with poor clinical prognosis in patients. There may be a synergistic effect influencing the invasion and metastasis of tumor cells, positioning them as potential novel therapeutic targets for patients with CRC.

13 days ago

Retrospective data • Journal

MMP11 (Matrix Metallopeptidase 11)

16d

RNA-Seq Analysis of Nintedanib Effects on Interstitial Pneumonia in Preoperative NSCLC Patients. (PubMed, Respir Med)

xCell2 analysis indicated reduced plasma cells and increased smooth muscle, muscle, adipocyte, and endothelial cells, suggesting normalization of tissue remodeling. Nintedanib appears to exert anti-inflammatory effects and promote tissue repair in non-tumor lung, while facilitating tissue remodeling in fibrotic areas, indicating potential benefits in patients with interstitial pneumonia and lung cancer.

16 days ago

Journal

AREG (Amphiregulin) • MMP11 (Matrix Metallopeptidase 11) • MUC6 (Mucin 6)

nintedanib

28d

Alterations in the transcriptional profile of genes in tumors as a prerequisite for personalization of treatment in breast cancer patients (PubMed, Arkh Patol)

Comparative mRNA expression analysis confirms that a short preoperative course of aromatase inhibitors induces a more potent and uniform molecular response, characterized by profound suppression of proliferation and complete inhibition of estrogen-dependent signaling. Tamoxifen therapy is also effective but results in less pronounced suppression of key targets and, crucially, may be accompanied by early activation of the MYC oncogene, a potential marker for resistance development.

28 days ago

Journal • PD(L)-1 Biomarker • IO biomarker

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • PTEN (Phosphatase and tensin homolog) • BCL2 (B-cell CLL/lymphoma 2) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CCND1 (Cyclin D1) • CCNE1 (Cyclin E1) • FGFR4 (Fibroblast growth factor receptor 4) • BIRC5 (Baculoviral IAP repeat containing 5) • TYMS (Thymidylate Synthetase) • AURKA (Aurora kinase A) • FOXA1 (Forkhead Box A1) • PPP2R2A (Protein Phosphatase 2, Regulatory Subunit B, Alpha) • PTTG1 (PTTG1 Regulator Of Sister Chromatid Separation, Securin) • BAG1 (BAG Cochaperone 1) • EMSY (EMSY Transcriptional Repressor BRCA2 Interacting) • GATA3 (GATA binding protein 3) • KRT5 (Keratin 5) • MMP11 (Matrix Metallopeptidase 11) • MYBL2 (MYB Proto-Oncogene Like 2) • SFRP1 (Secreted frizzled related protein 1) • TMEM45B (Transmembrane Protein 45B) • ANLN (Anillin Actin Binding Protein) • CCNB1 (Cyclin B1) • SCGB2A2 (Secretoglobin Family 2A Member 2) • ZNF703 (Zinc Finger Protein 703)

HER-2 negative • HER-2 expression

tamoxifen • letrozole • anastrozole

Identification of a Cuproptosis-Related Molecular Signature for Predicting Biochemical Recurrence in Prostate Cancer. (PubMed, Comb Chem High Throughput Screen)

This study initially identified two cuproptosis-related molecules based on the expression patterns of cuproptosis-related genes. In addition, we developed a new cuproptosisrelated molecular signature with great predictive performance for BCRFS and tumor immune environment using six DERRGs (including CALML5, MMP11, UBE2C, ANPEP, TMEM59L, COMP). These findings would be conducive to a deeper cognition of the potential mechanism of cuproptosis of PCa.

1 month ago

Journal • IO biomarker

MMP11 (Matrix Metallopeptidase 11) • ANPEP (Alanyl Aminopeptidase, Membrane) • UBE2C (Ubiquitin Conjugating Enzyme E2 C)

2ms

Association of Matrix Metalloproteinase-11 Genotypes With Taiwan Gastric Cancer Risk and Clinical Features. (PubMed, Anticancer Res)

While MMP-11 polymorphisms are not suitable as population-level screening markers for GACA risk, rs738791 and rs28382575 may serve as predictors for metastasis, and rs28382575 and rs738792 as modifiers of gene-environment interaction. Functional validation is warranted to elucidate the biological relevance of these findings in GACA progression.

2 months ago

Journal

MMP11 (Matrix Metallopeptidase 11)

2ms

Comprehensive bioinformatics and in vitro studies reveal the carcinogenic role and molecular basis of endocrine disruptors in prostate cancer. (PubMed, Front Cell Dev Biol)

Furthermore, we identify five natural compounds, notably Cryptotanshinone, that counteract the carcinogenic effects of EDs by targeting PLK1. These findings provide crucial molecular insights into ED-induced carcinogenesis and reveal promising targets for the prevention and intervention of PCa.

2 months ago

Preclinical • Journal • IO biomarker

CD38 (CD38 Molecule) • PLK1 (Polo Like Kinase 1) • MMP11 (Matrix Metallopeptidase 11)

3ms

MMP11 promotes immune escape in esophageal carcinoma cells via the PD-L1/c-Myc signaling pathway. (PubMed, Transl Oncol)

These findings suggest that MMP11 activates the PD-L1/c-Myc pathway, contributing to immune evasion and ESCA progression. Targeting MMP11 could thus serve as a potential therapeutic approach for ESCA immunotherapy.

3 months ago

Journal • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • MMP11 (Matrix Metallopeptidase 11)

PD-L1 expression

4ms

Epigenetic regulation of MMP-11 and -16 expression in human prostate cancer: the role of KDM6A. (PubMed, Epigenomics)

GSK-J4 increased histone3 lysine27 trimethylation (H3K27me3) enrichment at MMP-11 and -16 promoters, as shown by Chromatin Immunoprecipitation (ChIP). KDM6A demethylates H3K27me3 at MMP-11 and -16 promoters, sustaining their enhanced expression in PCa and revealing a novel epigenetic mechanism driving metastasis-associated protease expression.

4 months ago

Journal

KDM6A (Lysine Demethylase 6A) • KDM6B (Lysine Demethylase 6B) • MMP11 (Matrix Metallopeptidase 11) • MMP7 (Matrix metallopeptidase 7)

GSKJ4

5ms

Towards a transcriptomic biomarker for the classification of melanocytic neoplasms. (PubMed, PLoS Genet)

Furthermore, immunohistochemical staining showed consistent protein-level changes in MMP11 and PYGL. These results illuminate the potential for a transcriptomic biomarker to differentiate benign from malignant melanocytic neoplasms and improve the accuracy of melanoma diagnosis.

5 months ago

Journal

PRAME (Preferentially Expressed Antigen In Melanoma) • COL1A1 (Collagen Type I Alpha 1 Chain) • IGHG1 (Immunoglobulin Heavy Constant Gamma 1) • MMP11 (Matrix Metallopeptidase 11) • SLC4A4 (Solute carrier family 4 member 4) • CNTN1 (Contactin 1) • NALCN (Sodium Leak Channel, Non-Selective)